Logo

Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation

Share this

Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation

Shots:

  • The update in the development is based on ASPIRO P-I/II study results assessing AT132 in 12 patients aged≤ 5 yrs. following a pre-IND meeting of AT132 with FDA in Dec- 2018 for XLMTM- occurred due to mutations in the MTM1 gene
  • The FDA meeting is in response to review nonclinical- clinical- chemistry- manufacturing and controls (CMC) data leading to submission of AT132’s BLA. The ASPIRO P-I/II study resulted in safe and effective muscle biopsy
  • AT132 includes an AAV8 vector containing a functional copy of the MTM1 gene- encode myotubularin protein. AT132 has received FDA’s RMAT- Rare Pediatric Disease- FT and ODD- and PRIME and Orphan Drug designations by the EMA. The preclinical development of AT132 was conducted with Genethon

 /article Ref: PRNewswire | Image: Dennis McCain


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions